Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Prelude Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PRLD
Nasdaq
8731
https://preludetx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Prelude Therapeutics Inc
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
- Mar 5th, 2024 9:45 pm
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
- Feb 29th, 2024 9:05 pm
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
- Feb 17th, 2024 12:34 pm
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
- Feb 15th, 2024 9:05 pm
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the company
- Jan 14th, 2024 2:24 pm
Shell (SHEL) Resumes LNG Loading From Prelude Facility
- Jan 2nd, 2024 12:11 pm
Prelude Therapeutics Announces $25 Million Private Placement
- Dec 11th, 2023 2:34 pm
Shell's (SHEL) Prelude LNG Facility to Restart in December
- Nov 28th, 2023 4:46 pm
Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses
- Nov 5th, 2023 12:39 pm
Q3 2023 Abcellera Biologics Inc Earnings Call
- Nov 3rd, 2023 12:42 pm
Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress
- Nov 3rd, 2023 9:55 am
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
- Nov 1st, 2023 8:10 pm
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
- Nov 1st, 2023 8:05 pm
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
- Oct 14th, 2023 4:30 pm
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
- Oct 4th, 2023 4:00 pm
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
- Aug 29th, 2023 12:30 pm
10 Healthcare Stocks with Insider Buying
- Aug 17th, 2023 1:56 pm
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Aug 3rd, 2023 12:00 pm
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
- Jul 10th, 2023 12:13 pm
Insider Buying Alert: These 10 Stocks are Seeing Significant Insider Activity
- Jun 2nd, 2023 3:36 pm
Scroll